HTA and IDEAL
(a “NICE perspective”)

Bruce Campbell
Non-Executive Director Medicines and Healthcare products Regulatory Agency (MHRA)
Past Chair NICE Interventional Procedures and Medical Technologies Advisory Committees

IDEAL Conference
5 May 2017
Declaration

I have sweated blood
for Peter McCulloch
and application of IDEAL!
IDEAL is so clearly sensible

BUT

NICE:

• Has to evaluate procedures/devices on the evidence available at the time

• Is process-driven: no option for delay

• Has limited (some) influence on future evidence generation (“What do you want?!”)
NICE IP Research Recommendations

• Specify OUTCOMES but seldom DESIGN

• May specify “could/should include data collection”

• Often specifies particular registry and occasionally specific trial

Could IDEAL could inform recommendations?
Many conversations about IDEAL

• Look at IDEAL Stages of a series of new procedures seen by NICE IPAC

• What recommendations were made?

• What research was recommended?

How, therefore, might IDEAL be applied?
NICE Research capacity through its External Assessment Centres (EACs)

- Specific research is an option for MTAC recommendation (review in 2 years)
- EAC oversees collaboration, design, ethics

Could IDEAL assist this process (and subsequent, continuing evidence generation)?
Transition of device from one type of NICE guidance to another

**From** New Interventional Procedure evaluation
EVIDENCE: Safety/efficacy
Specifies *circumstances for its use*

**To** Medical Technology evaluation
EVIDENCE: Clinical and cost consequences/advantages
Encourages “*Evidence supports adoption …*”

**To** Technology Appraisal
EVIDENCE: Clinical and cost effectiveness
Mandates “*Should be offered to these patients …*”

How could IDEAL align with these transitions?
IDEAL-D

Stage 0: Important, but not traditionally part of IP/MT considerations – focus *clinical*

Stage 1: First in man never an issue for NICE

Stage 2-3 ‘merged’: Helpful simplification

Stage 4: Good data collection much earlier
Very helpful – fundamental to many decisions on new procedures
Evidence generation

**IDEAL** describes the framework for an overall strategy to:

- **Plan ahead for** regulators, HTA, payers, clinicians, patients

- **Maximise relevance** and value of evidence for these successive audiences